Dronabinol After Arthroscopic Surgery

Description

The purpose of the proposed study is to evaluate the efficacy of dronabinol for postoperative pain after arthroscopic surgery of the knee. The investigators hypothesize that dronabinol will relieve pain, reduce opioid consumption and will result in few negative side effects. If this pilot study shows promising results the investigators will expand the trial to include additional arthroscopic surgeries (hip, shoulder) and other types of orthopaedic surgery.

Conditions

Knee Osteoarthritis, Knee Injuries, Meniscus Tear, Synovitis of Knee, Knee Ligament Injury, Chondral Injury of Left Knee, Chondral Injury of Right Knee, Loose Body Knee

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the proposed study is to evaluate the efficacy of dronabinol for postoperative pain after arthroscopic surgery of the knee. The investigators hypothesize that dronabinol will relieve pain, reduce opioid consumption and will result in few negative side effects. If this pilot study shows promising results the investigators will expand the trial to include additional arthroscopic surgeries (hip, shoulder) and other types of orthopaedic surgery.

Dronabinol for the Treatment of Postoperative Pain After Arthroscopic Surgery: a Pilot Randomized Trial

Dronabinol After Arthroscopic Surgery

Condition
Knee Osteoarthritis
Intervention / Treatment

-

Contacts and Locations

Chicago

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 years or older
  • * Patient who will undergo arthroscopic surgery of the knee including, but not limited to,
  • * Meniscectomy
  • * Synovectomy
  • * Chondroplasty
  • * Loose body removal
  • * Patients under age 18 years
  • * Patients who cannot provide consent
  • * Patients who are pregnant, breast feeding, or are trying to become pregnant during the study period
  • * Patients with an allergy to any of the study drugs
  • * Patient who are lactose-intolerant
  • * Revision surgery
  • * Open surgery
  • * Comorbidities preventing surgery
  • * Patients with a history of mania, depression, or schizophrenia
  • * Patients taking any of the following drugs or supplements
  • * Anticholinergic agents
  • * Benzodiazepines
  • * Central nervous system depressants
  • * Droperidol
  • * Hydroxyzine
  • * Levomepromazine or methotrimeprazine
  • * Monoamine oxidase inhibitors
  • * Ritonavir
  • * Selective serotonin reuptake inhibitors
  • * Sympathomimetics
  • * St. John's Wort
  • * Current diagnosed alcohol or drug abuse
  • * Patients who cannot or will not abide by the medication restrictions listed below
  • * Participants must agree to abstain from using recreational or medical marijuana products or cannabidiol (CBD) in any form during the treatment period
  • * Participants should not drink alcohol or take other drugs while taking the study drug or hydrocodone/acetaminophen

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Northwestern University,

Vehniah K Tjong, MD, PRINCIPAL_INVESTIGATOR, Northwestern Feinberg School of Medicine

Study Record Dates

2025-06